Overview

A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections

Status:
Active, not recruiting

Trial end date:
2020-03-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to collect CGM, A1c and Quality of Life data in subjects with Type 2 diabetes before and after transitioning from Multiple Daily Injections to Basal plus Bolus with Afrezza® inhaled insulin. The primary objective is to evaluate the percentage of time spent in goal range without significant hypoglycemia. Additional objectives include evaluation of A1c and Quality of Life data. The expected outcomes are improvement of time in range, no change or improvement in A1c and favorable Quality of Life data

Phase:

Phase 4

Details

Lead Sponsor:

Diabetes and Glandular Disease Clinic

Collaborators:

DexCom, Inc.
Mannkind Corporation

Treatments:

Insulin
Insulin, Globin Zinc